Research graph
References from A call for action with the burden of cirrhosis in Australia. Local targets link to admitted publications; unresolved targets remain external evidence.
The hidden epidemic: the prevalence and impact of concurrent liver diseases in patients undergoing liver transplantation in Australia and New Zealand.
10.1097/txd.0000000000001345 · 2022 · External reference
Unresolved reference
External reference
Cancer control measures have prevented 230,000 deaths in Australia since the mid-1980s.
10.1016/j.anzjph.2025.100252 · 2025 · External reference
Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
10.1111/jgh.15009 · 2020 · External reference
Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
10.1111/jgh.16782 · 2025 · External reference
The global economic burden of cirrhosis and other chronic liver diseases: a health-augmented macroeconomic modeling study.
10.1097/hc9.0000000000000882 · 2026 · External reference
Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians.
10.1016/j.eclinm.2019.05.007 · 2019 · External reference
Age, period and cohort trends in hospital admissions for alcohol-related liver disease in Australia, 1993-2020.
10.1111/dar.14063 · 2025 · External reference
Healthcare utilisation and costing for decompensated chronic liver disease hospitalisations at a Victorian network.
10.1111/imj.15962 · 2023 · External reference
Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004-2013.
10.1053/j.gastro.2018.05.032 · 2018 · External reference
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
10.1016/j.jhep.2005.10.013 · 2006 · External reference
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis.
10.1016/j.jhep.2022.01.023 · 2022 · External reference
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
10.1016/s0140-6736(18)31875-0 · 2019 · External reference
A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
10.1097/hep.0000000000000862 · 2025 · External reference
Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study.
10.1111/imj.12166 · 2013 · External reference
Hepatocellular carcinoma surveillance in Australia: current and future perspectives.
10.5694/mja2.52442 · 2024 · External reference
A shared model of care for compensated cirrhosis is safe and acceptable to patients and general practitioners.
2026 · External reference
Unresolved reference
External reference
Surveillance for liver cancer in primary care: a systematic review of the evidence.
10.31128/ajgp-11-22-6619 · 2023 · External reference
Lessons from the implementation of the health care homes program.
10.5694/mja2.51537 · 2022 · External reference
Model for integrated care for chronic disease in the Australian context: Western Sydney integrated care program.
10.1071/ah18152 · 2019 · External reference
Improving primary care in Australia through the Australian primary care collaboratives program: a quality improvement report.
10.1136/bmjqs-2011-000165 · 2012 · External reference
Implementing a scalable, personalised, behaviour change digital health programme in primary care for type 2 diabetes treatment: the SCALE cluster-randomised study protocol.
10.1136/bmjopen-2025-101531 · 2025 · External reference
Learning from the implementation of a quality improvement intervention in Australian general practice: a qualitative analysis of participants views of a CVD preventive care project.
10.1186/s12875-022-01692-0 · 2022 · External reference
Unresolved reference
External reference
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease.
10.1186/s13063-025-09037-9 · 2025 · External reference
Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.
10.5694/mja2.70008 · 2025 · External reference
